|
1
|
Bray F, Sankila R, Ferlay J and Parkin DM:
Estimates of cancer incidence and mortality in Europe in 1995. Eur
J Cancer. 38:99–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heald RJ, Husband EM and Ryall RD: The
mesorectum in rectal cancer surgery-the clue to pelvic recurrence?
Br J Surg. 69:613–616. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Havenga K, Enker WE, Norstein J, Moriya Y,
Heald RJ, van Houwelingen HC and van de Velde CJ: Improved survival
and local control after total mesorectal excision or D3
lymphadenectomy in the treatment of primary rectal cancer: An
international analysis of 1,411 patients. Eur J Surg Oncol.
25:368–374. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Benson AB, Venook AP, Cederquist L, Chan
E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera
A and Grem JL: Colon cancer, version 1.2017, NCCN clinical practice
guidelines in oncology. J Natl Comp Cancer Network. 15:370–398.
2017. View Article : Google Scholar
|
|
5
|
Chua YJ: Pathological complete response:
Still a relevant endpoint in rectal cancer? The Lancet Oncology.
11:807–808. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maas M, Nelemans PJ, Valentini V, Das P,
Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R,
Haustermans K, et al: Long-term outcome in patients with a
pathological complete response after chemoradiation for rectal
cancer: A pooled analysis of individual patient data. Lancet Oncol.
11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Francois Y, Nemoz CJ, Baulieux J, Vignal
J, Grandjean JP, Partensky C, Souquet JC, Adeleine P and Gerard JP:
Influence of the interval between preoperative radiation therapy
and surgery on downstaging and on the rate of sphincter-sparing
surgery for rectal cancer: The Lyon R90-01 Randomized Trial. J Clin
Oncol. 17:23961999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garcia-Aguilar J, Chow OS, Smith DD,
Marcet JE, Cataldo PA, Varma MG, Kumar AS, Oommen S, Coutsoftides
T, Hunt SR, et al: Effect of adding mFOLFOX6 after neoadjuvant
chemoradiation in locally advanced rectal cancer: A multicentre,
phase 2 trial. Lancet Oncol. 16:957–966. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tulchinsky H, Shmueli E, Figer A, Klausner
JM and Rabau M: An interval >7 weeks between neoadjuvant therapy
and surgery improves pathologic complete response and disease-free
survival in patients with locally advanced rectal cancer. Ann Surg
Oncol. 15:2661–2667. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swellengrebel HA, Bosch SL, Cats A,
Vincent AD, Dewit LG, Verwaal VJ, Nagtegaal ID and Marijnen CA:
Tumour regression grading after chemoradiotherapy for locally
advanced rectal cancer: A near pathologic complete response does
not translate into good clinical outcome. Radiother Oncol.
112:44–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolthuis AM, Penninckx F, Haustermans K,
De Hertogh G, Fieuws S, Van Cutsem E and D'Hoore A: Impact of
interval between neoadjuvant chemoradiotherapy and TME for locally
advanced rectal cancer on pathologic response and oncologic
outcome. Ann Surg Oncol. 19:2833–2841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Habr-Gama A, Perez RO, Proscurshim I,
Nunes Dos Santos RM, Kiss D, Gama-Rodrigues J and Cecconello I:
Interval between surgery and neoadjuvant chemoradiation therapy for
distal rectal cancer: Does delayed surgery have an impact on
outcome? Int J Radiat Oncol Biol Phys. 71:1181–1188. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Supiot S, Bennouna J, Rio E, Meurette G,
Bardet E, Buecher B, Dravet F, Le Neel JC, Douillard JY, Mahé MA
and Lehur PA: Negative influence of delayed surgery on survival
after preoperative radiotherapy in rectal cancer. Colorectal Dis.
8:430–435. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edge SB and Compton CC: The american joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore HG, Gittleman AE, Minsky BD, Wong D,
Paty PB, Weiser M, Temple L, Saltz L, Shia J, Shia J and Guillem
JG: Rate of pathologic complete response with increased interval
between preoperative combined modality therapy and rectal cancer
resection. Dis Colon Rectum. 47:279–286. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patel UB, Taylor F, Blomqvist L, George C,
Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R,
et al: Magnetic resonance imaging-detected tumor response for
locally advanced rectal cancer predicts survival outcomes: MERCURY
experience. J Clin Oncol. 29:3753–3760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sauer R, Becker H, Hohenberger W, Rodel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cienfuegos JA, Baixauli J, Pastor C,
Arredondo J, Sola JJ, Arbea L, Chopitea A and Hernandez-Lizoain JL:
Long-term oncologic results in cancer of the rectum treated by
preoperative chemoradiotherapy and surgery: An analysis of 500
cases. Rev Esp Enferm Dig. 107:340–346. 2015.PubMed/NCBI
|
|
19
|
Lima IS, Yasui Y, Scarfe A and Winget M:
Association between receipt and timing of adjuvant chemotherapy and
survival for patients with stage III colon cancer in Alberta,
Canada. Cancer. 117:3833–3840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tevis SE, Kohlnhofer BM, Stringfield S,
Foley EF, Harms BA, Heise CP and Kennedy GD: Postoperative
complications in patients with rectal cancer are associated with
delays in chemotherapy that lead to worse disease-free and overall
survival. Dis Colon Rectum. 56:1339–1348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chau I, Brown G, Cunningham D, Tait D,
Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A and
Oates J: Neoadjuvant capecitabine and oxaliplatin followed by
synchronous chemoradiation and total mesorectal excision in
magnetic resonance imaging-defined poor-risk rectal cancer. J Clin
Oncol. 24:668–674. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao YH, Zhang X, An X, Cai MY, Zeng ZF,
Chen G, Kong LH, Lin JZ, Wan DS, Pan ZZ and Ding PR: Oxaliplatin
and capecitabine concomitant with neoadjuvant radiotherapy and
extended to the resting period in high risk locally advanced rectal
cancer. Strahlenther Onkol. 190:158–164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao YH, Lin JZ, An X, Luo JL, Cai MY, Cai
PQ, Kong LH, Liu GC, Tang JH, Chen G, et al: Neoadjuvant sandwich
treatment with oxaliplatin and capecitabine administered prior to,
concurrently with, and following radiation therapy in locally
advanced rectal cancer: A prospective phase 2 trial. Int J Radiat
Oncol Biol Phys. 90:1153–1160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Habr-Gama A, Perez RO, Sabbaga J, Nadalin
W, São Julião GP and Gama-Rodrigues J: Increasing the rates of
complete response to neoadjuvant chemoradiotherapy for distal
rectal cancer: Results of a prospective study using additional
chemotherapy during the resting period. Dis Colon Rectum.
52:1927–1934. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Larsen FO, Markussen A, Jensen BV, Fromm
AL, Vistisen KK, Parner VK, Linnemann D, Hansen RH, Johannesen HH
and Schou JV: Capecitabine and oxaliplatin before, during, and
after radiotherapy for High-Risk rectal cancer. Clin Colorectal
Cancer. 16:e7–e14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wan J, Liu K, Li K, Li G and Zhang Z: Can
dosimetric parameters predict acute hematologic toxicity in rectal
cancer patients treated with intensity-modulated pelvic
radiotherapy? Radiat Oncol. 10:1622015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Helbling D, Bodoky G, Gautschi O, Sun H,
Bosman F, Gloor B, Burkhard R, Winterhalder R, Madlung A, Rauch D,
et al: Neoadjuvant chemoradiotherapy with or without panitumumab in
patients with wild-type KRAS, locally advanced rectal cancer
(LARC): A randomized, multicenter, phase II trial SAKK 41/07. Ann
Oncol. 24:718–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engineer R, Ostwal V, Arya S, Gupta P,
Chopra S, Patil P, Jatal S and Saklani A: Additional chemotherapy
and salvage surgery for poor response to chemoradiotherapy in
rectal cancers. Asia Pac J Clin Oncol. 13:322–328. 2017. View Article : Google Scholar : PubMed/NCBI
|
